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ABSTRACT Antimalarial drug resistance is a substantial impediment to malaria con-
trol. The spread of resistance has been described using genetic markers, which are
important epidemiological tools. We carried out a temporal analysis of changes in al-
lele frequencies of 12 drug resistance markers over 2 decades of changing antimalarial
drug policy in Kenya. We did not detect any of the validated kelch 13 (k13) artemisinin
resistance markers; nonetheless, a single k13 allele, K189T, was maintained at a stable
high frequency (10%) over time. There was a distinct shift from chloroquine-resistant
transporter (crt)-76, multidrug-resistant gene 1 (mdr1)-86 and mdr1-1246 chloroquine
(CQ) resistance alleles to a 99% prevalence of CQ-sensitive alleles in the population, fol-
lowing the withdrawal of CQ from routine use. In contrast, the dihydropteroate synthe-
tase (dhps) double mutant (437G and 540E) associated with sulfadoxine-pyrimethamine
(SP) resistance was maintained at a high frequency (75%), after a change from SP to
artemisinin combination therapies (ACTs). The novel cysteine desulfurase (nfs) K65 allele,
implicated in resistance to lumefantrine in a West African study, showed a gradual sig-
niﬁcant decline in allele frequency pre- and post-ACT introduction (from 38% to 20%),
suggesting evidence of directional selection in Kenya, potentially not due to lumefan-
trine. The high frequency of CQ-sensitive parasites circulating in the population suggests
that the reintroduction of CQ in combination therapy for the treatment of malaria can
be considered in the future. However, the risk of a reemergence of CQ-resistant para-
sites circulating below detectable levels or being reintroduced from other regions re-
mains.
KEYWORDS Plasmodium falciparum, artemisinin resistance, chloroquine resistance,
k13, sulfadoxine-pyrimethamine resistance
Artemisinin-based combination therapies (ACTs) are recommended as the ﬁrst-linetreatment for uncomplicated Plasmodium falciparum malaria in all regions of
endemicity; however, drug resistance is an impediment to malaria control. Notably, resis-
tance to former ﬁrst-line antimalarials, chloroquine (CQ) and sulfadoxine-pyrimethamine
(SP), was imported to Africa via strains from South East (SE) Asia (1–3), although some drug
resistance markers to pyrimethamine emerged independently in Africa (4) and were
associated with increased malaria-related mortality in sub-Saharan Africa (5, 6). For this
reason, the recent emergence and spread of artemisinin resistance in SE Asia (7–9), as
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well as of multidrug-resistant (resistance to both artemisinin and the partner drug,
piperaquine) P. falciparum parasites in Cambodia and neighboring Vietnam (10, 11), are
now a major concern. Though isolated, the recent possible identiﬁcation of parasites
with high artemisinin survival rates in Equatorial Guinea and Uganda (12, 13) calls for
continued surveillance of artemisinin resistance markers in Africa.
The identiﬁcation of P. falciparum genetic mutations associated with antimalarial
drug resistance has provided molecular markers for surveillance of resistance, both in
real time and retrospectively, to assess geographic origins and migration patterns of
drug-resistant parasites (14). The use of such markers provided information on the
origin and spread of CQ (1) and sulfadoxine-pyrimethamine (SP) (2, 3). Likewise,
mutations in the kelch13 gene (k13), including F446I, N458Y, M476I, Y493H, R539T,
I543T, P553L, R561H, and C580Y, are enabling the detection and tracking of artemisinin
resistance in SE Asia (9, 15). Some of these mutations (Y493H, P553L, R561H, and C580Y)
have been observed at low frequencies (0.1%) in Africa (16). Whole-genome studies
of artemisinin-resistant parasites in SE Asia were shown to accumulate artemisinin
resistance predisposing mutations at other genetic loci (17). These mutations were
found in apicoplast ribosomal protein S10 precursor gene (arps10) codon V127M,
chloroquine resistance transporter (crt) codon I356T, ferredoxin (fd) codon D193Y, and
multidrug resistance (mdr) protein 2 codon T484I. While these mutations have been
identiﬁed in parasites from Africa, they occur at very low frequencies (arps-10-V127M,
0%; fd-D193Y, 0.1%;mdr2-T484I, 0.1%; crt-N326S, 0.8%) (16). Nonetheless, it is crucial for
regions outside SE Asia to monitor the emergence of artemisinin resistance signatures,
including the selection of markers associated with changes in antimalarial drug policy,
drug trials, and experimental analyses. Already, recent studies have shown that
artemether-lumefantrine (AL) selects for polymorphisms in the chloroquine resistance
transporter (crt) (K76 allele) and multidrug resistance 1 (mdr1) (N86/184F/D1246-NFD
haplotype) genes (18–21). Furthermore, the mdr1-NFD haplotype and an increase in
mdr1 copy number have been linked with reduced susceptibility to lumefantrine (LM)
and meﬂoquine (MQ), respectively (22–24). Moreover, several recent studies have
shown the selection of additional polymorphisms associated with ACT pressure and
warrant further investigation. A mutation (S69Stop) in the cysteine proteinase falcipain-2a
gene has previously been selected for after artemisinin in vitro selection pressure, using a
parasite isolate from Africa (15). A clinical trial conducted in western Kenya revealed
that 2 to 3 days of ACT treatment selected for parasites with either the 160N or 160T
allele in the AP-2 complex subunit mu gene (ap2-mu, S160N/T) and the allele 1528D in
the ubiquitin carboxyl-terminal hydrolase 1 gene (ubp-1, E1528D) (21). In The Gambia,
a temporal increase in the frequency of the K65 allele (K65Q) in the cysteine desulfurase
(nfs) gene was observed 6 years after the introduction of ACTs. Moreover, the 50%
inhibitory concentration (IC50) values for LM were signiﬁcantly higher in nfs-K65 wild-
type ﬁeld isolates than in the mutant 65Q isolates (25).
Mutations in the dihydrofolate reductase gene (dhfr 51I, 59R, and 108N triple
mutant) combined with mutations in the dihydropteroate synthetase gene (dhps 437G
and 540E double mutant) are associated with clinical and parasitological SP treatment
failure in East Africa (26–29). Although SP is the drug of choice for intermittent preventive
treatment in pregnant women (IPTp) (30), regional differences in drug resistance critically
impact the success of this intervention (31). An additional dhps mutation (A581G) has
been associated with reduced IPTp efﬁcacy when the prevalence of sextuple-mutant
(dhfr 51I/59R/108N and dhps 437G/540E/581G) parasites exceeds 37% (32). Also, al-
though its impact has yet to be elucidated, a novel dhps I431V allele has been detected
in West Africa, Cameroon, and Nigeria (33, 34).
These studies highlight the need for continued surveillance of known drug resis-
tance markers and novel markers to maintain the gains made in using ACTs and IPTp
in controlling malaria. crt, mdr1, and dhfr have well-described selection patterns in
response to the withdrawal of CQ and SP. Based on previous ﬁndings, there was
evidence of selection toward a predominance of wild-type alleles in crt and mdr1 and
toward the ﬁxation of the mutant dhfr alleles, over a 20-year period of changing
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antimalarial policy (35). Therefore, the aim of this study was to use the introduction of
ACTs as the pivotal point to test for evidence of selection in novel markers (ap2-mu,
falcipain-2a, k13, nfs, and ubp-1) whose impacts are not yet fully understood.
RESULTS
Genetic markers associated with artemisinin resistance. The k13 codon K189T
was the only polymorphism maintained at frequencies of 10%, while the rest of the
observed alleles were rare, including codon A578S, with frequencies barely reaching
2%. Other than K189T, the only other polymorphism observed across all time points is
the asparagine (Asn) repeat at codon 137. This repeat region included insertions of
between one and four asparagine residues, though at low frequencies,3%, compared
to SE Asia (60%) (36, 37). Many of the polymorphic codons occurred in the N-terminal
region compared to the C-terminal region, and from 1995/1996 to 2015/2016, the Ka/Ks
ratio for the whole k13 gene ranged from 2.25 to 5. Conversely, the Ka/Ks ratio for the
N-terminal region ranged from 2 to 9, while for the C-terminal region, the Ka/Ks ratio
was 1 throughout the same time period, except for 2012/2013, when there were no
polymorphisms in the C-terminal region. The observations in the N-terminal region are
comparable to those from other African studies, whereas fewer mutations were iden-
tiﬁed in SE Asian parasites (16). Comparisons with the MalariaGEN data set (16) and
other African studies (38, 39), revealed 9 loci that were unique to the Kiliﬁ population
and primarily occurred at only one time point over the 24-year study period. The codon
K189T had frequencies similar to those of parasites examined in East Africa (13%) and
West Africa (50%); however, the frequencies were much lower in SE Asia (0.005%).
Additionally, none of the k13 mutations associated with resistance in SE Asia were
identiﬁed (Table 1). Of the 13 haplotypes, the 3D7 haplotype (PK[N6]MAISKLQ) was
dominant over the entire sampling period, with frequencies of 70%. The second
dominant haplotype (PK[N6]MAISTLQ) showed stable frequencies from 1995/1996 to
2005/2006 (8.8% to 9.8%); however, it roughly doubled to 19.6% in 2012/2013 and then
dropped back to 8.8% in 2015/2016 (see Table S2 in the supplemental material).
Other putative genetic markers associated with artemisinin resistance. There
were no mutations identiﬁed in arps10, crt, and fd. However, a high-frequency (10%)
single-nucleotide polymorphism (SNP) (I492V) was identiﬁed in mdr2 in the 1995/1996
and 2015/2016 time points, and hence, the three middle time points were included.
Consequently, two additional polymorphisms were identiﬁed (I495V, 0.9% in 1998/1999
and V506I, 0.7% in 2005/2006), with the I492V polymorphism maintaining high fre-
quencies (between 13% and 30%; Table S3).
In ap2-mu, no signiﬁcant temporal trends were observed, and only two polymor-
phisms achieved frequencies of 10% across time, I100I and [7N]227[6N/8N/9N/10N].
Of note, the prevalence of S160N mutation was similar from 1995/1996 to 2015/2016,
except for a 2-fold increase from 9% in 1998/1999 to 24% in 2012/2013 that later
decreased to 16% in 2015/2016. Over the same period, the E163E allele showed similar
increases and decreases in frequency from 8.51% in 2005/2006 to 16.36% in 2012/2013
and down to 4.55% in 2015/2016) (Table S4). A total of 38 haplotypes were assembled,
with the 3D7 haplotype TRSKT[N7][Kx1]AG[N5][N4]AFI dominating across time (39%,
Table S9).
falcipain-2a was found to be the most polymorphic gene; however, the S69Stop
polymorphism was not identiﬁed (Table S5). Of the 71 haplotypes assembled, the 3D7
haplotype was not observed (Table S10). The only signiﬁcant temporal trend found was
that of codon S59F (2 5, P  0.02), with the 59F allele dropping from 13% in 1995
and 1996 to 5% in 2015/2016. From 2005/2006 and 2012/2013 through to 2015/2016,
the following alleles showed similar 2-fold increases and decreases in frequency: N4H,
A8I, P9P, H10N and E11E (17% to 8% and to 15%, respectively).
In ubp-1, only two polymorphisms were found to exceed 10% frequency across time
(range, 10 to 18%), the KYD repeat at codon 1520 and the KYE at codon 1526 (Table S6).
The E1528D polymorphism observed in previous studies from Kenya was not identiﬁed.
Additionally, from 2005/2006, 2012/2013, to 2015/2016, the following alleles showed
No Evidence of Artemisinin Resistance in Coastal Kenya Antimicrobial Agents and Chemotherapy
December 2019 Volume 63 Issue 12 e01067-19 aac.asm.org 3
 o
n
 D
ecem
ber 11, 2019 at LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
EDICINE
http://aac.asm
.org/
D
ow
nloaded from
 
2-fold increases and decreases in frequency: the KNE repeat at codon 1514 (5.5% to
11.6% and to 5.41%, respectively) and N1518N (5.6% to 11.7% and to 5.5%, respec-
tively). Of the 23 haplotypes, the 3D7 haplotype dominated throughout the sampling
period, and no signiﬁcant temporal trends were observed (Table S11).
Genetic markers associated with CQ, SP, and lumefantrine resistance. Three
polymorphic codons (M74I, N75E, and K76T) were identiﬁed in the crt gene in 2015/
2016 and 2017/2018. Mutant alleles at codons 74I, 75E, and 76T dominated during the
pre-ACT period, and there was a distinct shift to the wild-type alleles (M74, N75, and
K76) in the post-ACT period, almost reaching ﬁxation (99%) (2 181, P  0.001; Table
2). There was a signiﬁcant decline in the frequency of the CQ-resistant (CQR) haplotype
(CVIET) over time, reaching 1% in 2017 to 2018 and a sharp increase in the frequency
of the CQ-sensitive (CQS) haplotype (CVMNK) from 7% in 1998/1999 to 99% in 2017/
2018 (2 181, P  0.001; Fig. 1A and Table S12).
Five polymorphic codons were identiﬁed in mdr1 in 2015/2016 and 2017/2018, as
follows: N86Y, G102G, G182G, F184Y, and D1246Y. mdr1 codons 86Y and 1246Y also
showed a distinct shift from mutant alleles in the pre-ACT period (40 to 70%) to
wild-type alleles N86 and D1246, nearly approaching ﬁxation (99%) (2 103, P 
0.001 and 2 85, P  0.001, respectively) post-ACT introduction. In contrast, the
mutant 184F allele increased in frequency during the post-ACT period (33 to 54%,
2 15.8, P  0.001; Table 2). There was a notable change in haplotype frequencies
between the 3D7 haplotype (NYD) and mutant NFD haplotype. NYD increased sharply
to 64% in 2012/2013, decreased to 40% in 2015/2016, and later rose to 55% in
2017/2018 to become the dominant haplotype. The mutant haplotype NFD followed an
TABLE 1 k13 SNP frequenciesa
Codon Nucleotide
Codon (nucleotide) for: Frequency (% [no.]) during yr:
Wild type Mutant 1995/1996 1998/1999 2005/2006 2012/2013 2015/2016
38 112 S (A) C (T) 0 (132) 0 (117) 0 (133) 0 (114) 0.7 (135)
96 287 P (C) Q (A) 0 (132) 0.7 (126) 0 (133) 0 (114) 0 (137)
108 322 K (A) E (G) 0 (95) 0.7 (126) 0.7 (133) 0 (114) 0 (137)
119b 355 L (T) L (C) 0.7 (132) 0 (126) 0.7 (133) 0 (114) 0 (136)
126b 377 T (C) N (A) 0.7 (132) 0.7 (126) 0 (133) 0 (114) 0 (136)
134 401 I (T) S (G) 0 (126) 0.7 (126) 0 (133) 0 (114) 0 (135)
136 406 H (C) N (A) 0.7 (126) 0 (126) 0.7 (133) 1 (115) 0 (135)
137b,c 409 Nx6 (6xAAT) Nx7 (7xAAT) 2 (124) 1 (126) 3 (133) 3 (115) 0.7 (134)
Nx8 (8xAAT) 3 (124) 1 (126) 0 (133) 1 (115) 1 (134)
Nx9 (9xTAA) 0 (124) 0 (126) 0 (133) 1 (115) 0 (134)
Nx10 (10xTAA) 0 (124) 0 (126) 0 (133) 1 (115) 0 (134)
148 443 I (T) T (C) 0 (122) 0 (104) 0.7 (133) 0 (114) 0 (133)
149b 445 T (A) S (T) 0 (122) 0.7 (127) 0 (133) 0 (114) 1 (133)
157b 469 M (A) V (G) 0 (122) 0.7 (127) 0 (133) 0 (114) 0 (132)
174 520 A (G) S (T) 0 (95) 0 (125) 0 (133) 0.8 (115) 0 (83)
178b 532 I (A) L (T) 1 (86) 0 (126) 0 (128) 0 (108) 0 (68)
182b 544 S (T) T (A) 0 (95) 3 (125) 1 (132) 0 (117) 0 (87)
189b 566 K (A) T (C) 8 (82) 15 (126) 10.6 (132) 15 (115) 13 (71)
567 K (A) T (T) 0 (79) 0 (124) 0.7 (132) 0.8 (115) 0 (71)
192c 574 T (A) A (G) 0 (72) 0 (125) 0.7 (131) 0 (104) 0 (74)
258b 772 L (T) M (A) 1 (91) 1 (100) 0 (105) 0 (79) 0.8 (116)
271b 813 Q (G) H (T) 0 (93) 0 (69) 0.9 (107) 0 (81) 0 (121)
354 1060 I (A) V (G) 0.7 (132) 0 (136) 0 (126) 0 (103) 0 (138)
417b 1251 P (C) P (T) 0.7 (135) 0 (140) 0.7 (126) 0 (105) 0 (129)
469b 1407 C (C) C (T) 0 (138) 0 (139) 2 (126) 0 (102) 0 (139)
487 1461 V (A) V (T) 0 (139) 0.7 (127) 0 (130) 0 (105) 0 (142)
578b,c 1732 A (G) S (T) 1 (137) 0.7 (127) 0.7 (127) 0 (117) 0.7 (142)
1733 A (C) V (T) 0.7 (137) 0 (131) 0 (127) 0 (117) 0 (142)
589b 1767 V (C) V (T) 0 (136) 0 (123) 0 (127) 0 (117) 0.7 (139)
aThe numbers of samples successfully genotyped per time point include 148 in 1995/1996, 146 in 1998/1999, 146 in 2005/2006, 132 in 2012/2013, and 148 in 2015/
2016. No sequences with mixed bases were identiﬁed. Frequency data are presented as the percentage of sequences that carried a mutation out of the total number
of sequences that had data for that locus (n). Polymorphisms in codons 30 to 417 fall in the N-terminal region, while those from 469 to 589 fall in the C-terminal
region. SNPs not marked as described in footnotes b and c appear to be unique to the Kiliﬁ parasite population. In gray are frequencies of zero.
bN-terminal SNPs that have been identiﬁed in parasites from Africa.
cN-terminal SNPs that have been identiﬁed in parasites from SE Asia.
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opposite pattern, rising to 55% in 2015/2016 and later decreasing to 41% in 2017/2018.
The triple-mutant haplotype YYY was no longer detected in the population post-ACT
(Fig. 1B and Table S12), and there was no signiﬁcant temporal trend observed for the
haplotype frequencies. The mdr1-G102G and G182G identiﬁed in 2015/2016 and 2017/
2018 at low frequencies (1 to 7%) were not genotyped in an earlier study (35); hence,
we could not describe their associations with changing antimalarial drug policy.
S436A, A437G, K540E, and A581G dhps polymorphic codons were identiﬁed across
all time points, and the I431V mutation was not identiﬁed. The mutant (437G and 540E)
alleles dominated in the post-ACT period (68 to 91%; 2 82.7, P 0.001 and 2 153,
P 0.001, respectively). The SP-sensitive haplotype (SAKA) decreased in frequency over
time and was no longer detectable in 2015/2016 (Table 2), while the single-mutant
haplotype (SGKA) decreased gradually to 9% in 2015/2016 and the double-mutant
haplotype (SGEA) rose in frequency from 10% to 85% in 2015/2016 (Fig. 1C and Table
S12). There was a signiﬁcant temporal trend between the two dominant haplotypes,
SAKA and SGEA (2 91, P  0.001).
In nfs, only codon K65Q was found to have a signiﬁcant, albeit marginal, trend pre-
and post-ACT introduction (2 4.4, P  0.04). It was also in high linkage disequili-
brium with codons S62N and E67G. The 2005/2006 period appears to be the point at
which the mutant allele 65Q and wild-type 65K diverge in frequency in opposite
directions, with the wild-type 65K decreasing and the mutant allele 65Q increasing in
frequency (Fig. 1D and Table S7). The 3D7 haplotype was the seventh most dominant
of all the 24 haplotypes, and there were no signiﬁcant temporal trends in haplotype
frequencies (Table S13). Additionally, we examined for spatial variation for crt, mdr1,
and nfs and did not see any variation in alleles according to geographical area (Table
S15).
serine-tRNA ligase, putative gene. Serine-tRNA ligase, a marker not associated
with resistance or drug selection, had only one polymorphic codon observed across all
time points (L84V), with frequencies ranging between 2 and 5%, while the rest were
rare (5%) (Table S8). A total of 15 haplotypes were observed, and only the 3D7
haplotype occurred across all time points and with frequencies of 80%, with the rest
of the haplotypes being rare (5%) (Table S14).
DISCUSSION
The stable frequencies of the common k13 A578S African mutation and K189T (16,
40, 41) suggest that these mutations are not under selective pressure from artemisinin.
TABLE 2 crt, mdr1, and dhps SNP frequenciesa
Gene Codon Nucleotide
Codon (nucleotide)
for: Frequency (% [no.]) during yr:
Wild type Mutant 1995/1996 1998/1999 2005/2006 2012/2013 2015/2016 2017/2018
crt 74 222 M (G) I (T) 62.03 (80) 93.2 (103) 50.98 (102) 18.29 (82) 3.16 (94) 1.1 (92)
75 223 N (A) E (G) 62.03 (80) 93.2 (103) 50.98 (102) 18.29 (82) 3.16 (94) 1.1 (92)
75 225 N (T) E (A) 62.03 (80) 93.2 (103) 50.98 (102) 18.29 (82) 3.16 (94) 1.1 (92)
76 227 K (A) T (C) 62.03 (80) 93.2 (103) 50.98 (102) 18.29 (82) 3.19 (94) 1.1 (92)
mdr1 86 256 N (A) Y (T) 57.14 (57) 72.84 (81) 57.45 (47) 2.08 (48) 2.8 (107) 1.22 (82)
102 306 G (T) G (C) ND ND ND ND 1.9 (105) 7.41 (81)
182 546 G (T) G (G) ND ND ND ND 2.56 (78) 0 (89)
184 551 Y (A) F (T) 30.56 (57) 13.58 (81) 29.79 (47) 33.33 (48) 54.43 (79) 42.5 (80)
1246 3736 D (G) Y (T) 37.5 (57) 64.2 (81) 38.3 (47) 0 (48) 2.8 (107) 1.14 (88)
dhps 436 1306 S (T) A (G) 0 (85) 2.42 (124) 0 (80) 0 (21) 0 (24) NA
437 1310 A (C) G (G) 32.94 (85) 37.9 (124) 86.49 (74) 78.57 (28) 0 (26) NA
540 1618 K (A) E (G) 10.42 (196) 28.12 (128) 83.17 (101) 68.29 (41) 91.3 (45) NA
581 1742 A (C) G (G) 0 (93) 0 (120) 0 (89) 0 (54) 3.03 (32) NA
aThe numbers of samples successfully genotyped per time point include crt, 103 in 2015/2016 and 91 in 2017/2018 and no sequences with mixed bases identiﬁed;
mdr1, 130 in 2015/2016 and 88 in 2017/2018 and no sequences with mixed bases identiﬁed; dhps, 99 in 1995/1996, 137 in 1998/1999, 130 in 2005/2006, 80 in 2012/
2013, and 72 in 2015/2016, with two sequences having mixed bases in 1998/1999. Frequency data are presented as the percentage of sequences that carried a
mutation out of the total number of sequences that had data for that locus (n). For dhps 2017/2018 and crt (codons 102 and 182 in 1995/1996, 1998/1999, and
2005/2006, respectively), no data (NA) was available because they were not genotyped. ND, not determined. In gray are frequencies of zero.
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Notably, a recent study conﬁrmed that the A578S mutation does not confer resistance
to artemisinin (41). The codon 137 Asn repeats, found at lower frequencies than in SE
Asia, have been associated with day 3 positivity (36) and cooccur with k13 propeller
mutants (37). However, it is not known how these polymorphisms modulate artemisinin
resistance, and further studies are needed to investigate this. Similar to parasites from
Africa, the N-terminal region of k13 had higher Ka/Ks ratios than did the C-terminal
region, contrary to k13 data from SE Asia (16), implying that parasites from Africa
acquire more changes in the N-terminal region than the C-terminal region. Moreover,
as has been observed in parasites from Africa (16), there was no artemisinin resistance-
predisposing mutations, and themdr2 I492V mutation showed no evidence of selection
over time. This mutation (I492V) has also been identiﬁed at 100% frequency (n 38) in
Suriname (42).
The withdrawal of CQ (43) has resulted in the rapid decline in CQR alleles crt 76T and
mdr1 86Y and mdr1 1246Y in Kiliﬁ. Nationally, a decline in CQR resistant alleles has
previously been observed on the South Coast of Kenya, with the crt 76T and mdr1 86Y
alleles decreasing from 88% to 63% and 75% to 54% from 1998 to 2008, respectively
(44). In western Kenya, where malaria transmission is holoendemic, the crt 76T, mdr1
86Y, and mdr1 1246Y alleles dropped from 86% to 2%, 92% to 1%, and 67% to 6%
FIG 1 crt, mdr1, and dhps haplotypes and nfs codon K65Q frequencies over time. (A) The crt-sensitive haplotype (CVMNK) decreased from 1995/1996 to
1998/1999 and increased onwards to almost ﬁxation in 2017/2018, while the crt-resistant haplotype (CVIET) followed an opposite pattern. (B) The 3D7 mdr1
haplotype NYD had was the least prevalent in comparison to the mutant haplotypes NFD, YYD, and YYY pre-ACT introduction. The triple-mutant YYY was
undetectable after 2005/2006, while the 3D7 NYD and mutant NFD haplotypes started to increase in the population after 2005/2006. The mutant YYD and NFY
haplotypes decreased to almost zero in 2017/2018. (C) The SP-sensitive haplotype (SAKA) was on a decline from 1995/1996 and was undetectable in the
population after 2012/2013. The SP-resistant double-mutant haplotype SGEA was on the increase from 1995/1996 and reached 80% frequency in 2015/2016.
The single-mutant haplotype SGKA was the least prevalent throughout the sampling period. (D) The two nfs K65Q alleles appear to have stable frequencies
from 1995/1996 to 2005/2006, but the frequency of K65 starts to drop after 2005/2006, while that of 65K starts to increase after 2005/2006. In gray are the 95%
conﬁdence intervals.
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between the years 2003 and 2014, respectively (45). In the same region, CQ median IC50
values decreased signiﬁcantly, from a median of 92 to 22 from 2008 to 2011 (P 0.001)
(46). Therefore, a national rerollout of CQ in the next few years is a possibility. However,
it is also likely that resistant parasites may remain in the population below detectable
levels, and reemergence from these parasites or the reintroduction from surrounding
areas could be rapid. Regardingmdr1, the disappearance of the triple-mutantmdr1-YYY
is also likely to be the result of CQ withdrawal. Likewise, the oscillation of themdr1-NFD
with the NYD (wild type) at a high frequency post-ACT introduction suggests that the
NYD haplotype is likely to have risen in frequency due to the absence of CQ, restoring
the wild-type parasite population, while the increase in the NFD haplotype frequency
may be attributable to artemether-lumefantrine (AL) pressure (19).
The high frequency of SP resistance markers in Kenya (35) may be attributable to the
continued distribution of SP for malaria case management in the private sector (47).
Though SP maintains its utility in IPTp, the loss of IPTp efﬁcacy has been noted when
the prevalence of the sextuple-mutant (dhfr 51I/59R/108N and dhps 437G/540E/581G)
parasites exceeds 37% (32), as seen in some sub-Saharan African settings. Conse-
quently, the dhps 581G mutation needs to be monitored, given that it ﬁrst occurs in our
population in 2015/2016 at 3%. The dhps I431V allele was not detected, and its
distribution could be restricted to West Africa (33, 34).
We noted a decline in the nfs K65 wild-type allele in the Kiliﬁ population since the
introduction of AL in 2004, contrary to recent ﬁndings from The Gambia in West Africa
(25), and it appears that there is an opposite trend of the K65 allele in this East African
population. The Gambian parasites have shown increasing tolerance to lumefantrine
(LM) in a study conducted between 2013 and 2015 (48); however, drug trials with AL
in western Africa, including The Gambia, show that AL is still highly efﬁcacious (49).
Perhaps these discordant observations are due to differences in allele frequencies of
other loci, such as pfmdr1, between East and West Africa (50), or differences in drug
policy, such as the extensive use of amodiaquine (AQ) in West Africa compared to East
Africa (51). AQ shows activity against CQR parasites, like in West Africa, where the
prevalence of CQR parasites is still high (52). However, in East Africa, there are reports
of AQ resistance (53, 54) and AQ-resistant parasites are sensitive to LM (19). Thus, this
geographical difference in drug use, the inverse resistance proﬁle between AQ and LM,
and the predominance of CQS parasites in East Africa suggest that AQ may drive LM
resistance in West Africa.
The distinct change in frequency of resistance-associated alleles observed with crt,
mdr1, dhps, and nfs were not seen in the other genes we evaluated, ap2-mu, falcipain-
2a, and ubp-1. Notably, ap2-mu 160N showed no evidence of selection and has not
been observed in parasites in SE Asia, where artemisinin resistance is common (16).
Therefore, it appears to be restricted to Africa, as it has also been observed in Ghana
(55). Recent evidence points to a different mutation, I592T (not detected in this
population), that showed increased ring-stage survival following a dihydroartemisinin
pulse (56). Further work is required to evaluate the potential role of ap2-mu mutations
on the ACT response.
falcipain-2a was the most polymorphic gene in this study, and this can be attributed
to drug pressure, as it is associated with the parasite’s digestive vacuole, the target of
many antimalarials (57). Nonetheless, The S69Stop mutation that results is artemisinin
resistance in vitro (15) was not identiﬁed in our population. However, we found a
signiﬁcant temporal increase in the S59 allele post-ACT introduction, potentially due to
AL pressure. It remains to be seen what the role of falcipain-2a is in modulating
artemisinin resistance.
We did not identify the ubp-1 1528D mutation, contrary to a study by Henriques et
al. (21), which showed that its frequency increased post-ACT treatment, although it has
been found at a prevalence of 7.4% in Ghana (55). A different ubp-1 SNP (R3138H),
outside the region we genotyped, has also been associated with artemisinin resistance
on the Thai-Myanmar border (Cerqueira et al. [58]). Like ap2-mu and falcipain-2a, this
calls for further work to understand the role of ubp-1 as a marker of ACT resistance.
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We observed 2-fold increases or decreases in the frequencies of alleles and haplo-
types of several genes, followed by a shift back to the original frequency in the
durations spanning 2012/2013, 2015/2016, and through to 2017/2018. This could be
due to the abrupt change in drug policy from SP to ACTs and hence the initial selection
of long haplotypes followed by recombination breaking down the haplotype structure
as the parasite adapts to changes in drug pressure. The lack of spatial variation in allele
frequency is consistent with previous reports at this geographical scale (59); however,
we had limited power to do a more detailed analysis beyond north and south Kiliﬁ.
Following the introduction of ACTs in 2004, there has been a rapid increase in the
CQ-sensitive population to near ﬁxation, and this reignites the debate on the use of CQ
for malaria treatment, such as in combination therapy. On the other hand, there is still
a need for careful monitoring of the dhps A581G locus, since SP has proved useful in
IPTp, signiﬁcantly reducing morbidity in pregnant women (32). The decline in the novel
marker (nfs), which potentially confers resistance to LM, contrary to the observations
made in The Gambia, calls for additional studies to determine its role as a potential
drug target. The artemisinin resistance-conferring SE Asian mutations in k13, such as
C580Y, have not been identiﬁed in Kiliﬁ, and many of the SNPs occurred in the
N-terminal region of the gene with no evidence of drug selection. Consequently, due
to a lack of the validated molecular markers of artemisinin and lumefantrine resistance,
there appears to be no problem of resistance in the population; however, continued
surveillance remains a requirement.
MATERIALS AND METHODS
Study design. We used parasite DNA extracted from frozen blood obtained in 1995/1996, 1999/
2000, 2006/2007, and 2012/2013 from a previous study (35) and from additional samples from 2015/2016
and 2017/2018 from this new study. One hundred ﬁfty samples were collected for each time point,
except for 2017/2018, in which 109 samples were used. Blood samples were obtained from patients
presenting to Kiliﬁ County Hospital with malaria (1 month to 15 years of age). The samples span 24 years
of changing drug policy (Fig. 2). Ethical approval for this study was obtained from the ethics review
committee of the Kenya Medical Research Institute under protocol number SERU 3149.
Sample preparation, PCR, and capillary sequencing. P. falciparum genomic DNA was extracted
from frozen blood using the Qiagen DNA blood minikit (Qiagen, UK), as per the manufacturer’s
instructions. Amplicons were generated from the following genes using primers from previous studies
and primers designed in this study (Table S1): crt (PF3D7_0709000), mdr1 (PF3D7_0523000), dhps
FIG 2 Schematic showing the time points from which parasite populations were genotyped. Also indicated are historical highlights of antimalarial drug
resistance in Kiliﬁ versus South East Asia. Cited are studies by Noedl et al. (7), Dondorp et al. (8), Ariey et al. (15), Shretta et al. (43), Mwai et al. (64), Amin et
al. (65), and Fogh et al. (66).
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(PF3D7_0810800), nfs (PF3D7_0727200), k13 (PF3D7_1347700), ap2mu (PF3D7_1218300), falcipain-2a
(PF3D7_1347700), ubp-1 (PF3D7_0104300), and serine-tRNA ligase, putative gene (PF3D7_0717700).
Additionally, four artemisinin resistance-predisposing mutations in arps10 (PF3D7_1460900), crt
(PF3D7_0709000), fd (PF3D7_1318100), and mdr2 (PF3D7_1447900) were genotyped. Given that these
mutations in these genes have been identiﬁed at low frequencies (1%) in Africa (16), genotyping was
ﬁrst done for the 1995/1996 and 2015/2016 time points, and then the remaining time points were
included if SNPs with 10% frequency were identiﬁed. We used the Expand high-ﬁdelity PCR system,
0.5 l of template DNA, and primers and PCR conditions indicated in Table S1. The ﬁnal reaction volume
was 10 l, and the PCR ampliﬁcation products were visualized on 1% agarose gels stained with RedSafe
nucleic acid staining solution (iNtRON Biotechnology DR). PCR-negative samples were taken through a
second and ﬁnal round of PCR with 0.75 l of template DNA. Positive PCR products were puriﬁed using
ExoSAP-IT (Thermo Fisher Scientiﬁc) and directly sequenced using the PCR primers, additional internal
primers (Table S1), and BigDye Terminator v3.1 cycle sequencing kit v3.1 (Applied Biosystems, UK).
Capillary sequencing was done at the International Livestock Research Institute (ILRI, Kenya) using an ABI
3730xl capillary sequencer (Applied Biosystems).
Sequence analysis. Sequence assembly was performed in CLCMainWorkbench v7.9.1 (Qiagen, UK), and
SNPs were identiﬁed and called based on the respective 3D7 reference sequences. Nucleotide positions which
displayed a peak within a peak in the sequence chromatograms were noted as “mixed.” Consensus sequences
were extracted from the sequence assemblies using CLC Genomics Workbench v9.5.3 and used to construct
multiple-sequence alignments in Clustal Omega v1.2.1 (60). SNP frequencies were calculated per gene per
time point, and singletons were conﬁrmed by an additional round of PCR and sequencing.
Statistical analysis. Nucleotide sequences were translated into amino acid sequences in AliView
v1.26 (61). Haplotypes were then generated based on the amino acid residues from all the polymorphic
codons that cut across all sequences and time points after excluding sequences with mixed bases. Data
for crt andmdr1 from the 1995 to 2013 time points were obtained from a previously published study (35).
The difference in the prevalences of alleles and haplotypes in pre-ACT and post-ACT periods was
evaluated using a chi-square test. For this analysis, 2005/2006 was used as the point to divide the data
into the pre- and post-ACT periods, since we do not expect complete ACT coverage following its formal
introduction in 2004; hence, data for 2005/2006 were excluded from this part of the analysis. Addition-
ally, it was the crossover point for the shift in high frequency from the crt 76T to crt K76 allele. The
chi-square test for alleles included data for all SNPs with 10% frequencies at any time point, while for
haplotypes, we included only the sequences that had data across all loci and with frequencies of 10%
at any time point. Additionally, the chi-square test for haplotypes was conducted only for the two
dominant haplotypes. All plots were generated using ggplot2 v3.1.1 (62) and ggpubr v0.2 packages (63)
in R v3.6.0 (R Core Team, 2014). The Ka/Ks ratio was calculated for k13 by dividing the number of
nonsynonymous substitutions per nonsynonymous site (Ka) by the number of synonymous substitutions
per synonymous site over time.
Data availability. The nucleotide sequence data reported in this paper are available in the GenBank
database under the accession numbers MN373285 to MN373771 (ap2-mu), MN373772 to MN374234
(dhps), MN374235 to MN374817 (falcipain-2a), MN374818 to MN375065 (fd), MN375066 to MN375759
(k13), MN375760 to MN376049 (mdr1), MN376050 to MN376651 (mdr2), MN376652 to MN377106 (nfs),
MN377107 to MN377726 (serine tRNA ligase gene), and MN377727 to MN378298 (ubp1). However,
sequences for arps10 and crt could not be deposited, as GenBank does not accept sequences under
200 bp.
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